These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 2834409)

  • 1. Maintenance of the ratio of bioactive to immunoreactive follicle-stimulating hormone in normal men during chronic luteinizing hormone-releasing hormone agonist administration.
    Pavlou SN; Dahl KD; Wakefield G; Rivier J; Vale W; Hsueh AJ; Lindner J
    J Clin Endocrinol Metab; 1988 May; 66(5):1005-9. PubMed ID: 2834409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN; Wakefield G; Schlechter NL; Lindner J; Souza KH; Kamilaris TC; Konidaris S; Rivier JE; Vale WW; Toglia M
    J Clin Endocrinol Metab; 1989 Feb; 68(2):446-54. PubMed ID: 2537334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin and steroid secretory patterns during chronic treatment with a luteinizing hormone-releasing hormone agonist analog in men.
    Evans RM; Doelle GC; Alexander AN; Uderman HD; Rabin D
    J Clin Endocrinol Metab; 1984 May; 58(5):862-7. PubMed ID: 6423661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor.
    Roman SH; Goldstein M; Kourides IA; Comite F; Bardin CW; Krieger DT
    J Clin Endocrinol Metab; 1984 Feb; 58(2):313-9. PubMed ID: 6198331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.
    Klibanski A; Jameson JL; Biller BM; Crowley WF; Zervas NT; Rivier J; Vale WW; Bikkal H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):81-6. PubMed ID: 2535852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of concordant luteinizing hormone (LH), testosterone, and alpha-subunit pulses after LH-releasing hormone antagonist administration in normal men.
    Pavlou SN; Veldhuis JD; Lindner J; Souza KH; Urban RJ; Rivier JE; Vale WW; Stallard DJ
    J Clin Endocrinol Metab; 1990 May; 70(5):1472-8. PubMed ID: 2110578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
    Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
    J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent long-term administration of a potent gonadotropin-releasing hormone agonist in normal men.
    Doelle G; Linde R; Alexander N; Kirchner F; Vale W; Rivier J; Rabin D
    Int J Fertil; 1982; 27(4):234-7. PubMed ID: 6131043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the luteinizing hormone-releasing hormone (LHRH) analog D-Trp6-Pro9-NEt-LHRH on the pituitary-gonadal axis of prepubertal rhesus monkeys.
    Cassorla F; Renquist D; Barnard D; Munabi AK; Cutler GB; Loriaux DL
    Biol Reprod; 1984 Jun; 30(5):1130-4. PubMed ID: 6428479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin and alpha-subunit secretion during long term pituitary suppression by D-Trp6-luteinizing hormone-releasing hormone microcapsules as treatment of precocious puberty.
    Lahlou N; Roger M; Chaussain JL; Feinstein MC; Sultan C; Toublanc JE; Schally AV; Scholler R
    J Clin Endocrinol Metab; 1987 Nov; 65(5):946-53. PubMed ID: 2959680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men.
    Pavlou SN; Debold CR; Island DP; Wakefield G; Rivier J; Vale W; Rabin D
    J Clin Endocrinol Metab; 1986 Aug; 63(2):303-8. PubMed ID: 3088019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pituitary-testicular axis suppression in utero and during the early neonatal period with a long-acting luteinizing hormone-releasing hormone analog on genital development, somatic growth, and bone density in male cynomolgus monkeys in the first 6 months of life.
    Liu L; Cristiano AM; Southers JL; Reynolds JC; Bacher J; Brown G; Gilley RM; Tice TR; Banks SM; Loriaux LD
    J Clin Endocrinol Metab; 1991 Nov; 73(5):1038-43. PubMed ID: 1939516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone.
    Pavlou SN; Interlandi JW; Wakefield G; Rivier J; Vale W; Rabin D
    J Androl; 1986; 7(4):228-33. PubMed ID: 3528106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of deslorelin dose in the treatment of central precocious puberty.
    Pescovitz OH; Barnes KM; Cutler GB
    J Clin Endocrinol Metab; 1991 Jan; 72(1):60-4. PubMed ID: 1898743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women.
    Matikainen T; Ding YQ; Vergara M; Huhtaniemi I; Couzinet B; Schaison G
    J Clin Endocrinol Metab; 1992 Sep; 75(3):820-5. PubMed ID: 1517372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
    Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y
    J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay.
    Jaakkola T; Ding YQ; Kellokumpu-Lehtinen P; Valavaara R; Martikainen H; Tapanainen J; Rönnberg L; Huhtaniemi I
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1496-505. PubMed ID: 2140831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biologic activity of a potent analogue of gonadotropin-releasing hormone in normal and hypogonadotropic men.
    Crowley WF; Beitins IZ; Vale W; Kliman B; Rivier J; Rivier C; McArthur JW
    N Engl J Med; 1980 May; 302(19):1052-7. PubMed ID: 6767977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of active and passive immunization with luteinizing hormone-releasing hormone on serum luteinizing hormone and follicle-stimulating hormone levels and the ultrastructure of the pituitary gonadotrophs in castrated male rats.
    Arimura A; Shino M; de la Cruz KG; Rennels EG; Schally AV
    Endocrinology; 1976 Jul; 99(1):291-303. PubMed ID: 780100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.